Open AccessDAPA-HF trial signals the birth of ‘diabetic cardiology’ and more
Author(s) -
Kerolos Wagdy,
Peter Selwanos
Publication year - 2020
Publication title -
global cardiology science and practice
Language(s) - English
Resource type - Journals
ISSN - 2305-7823
DOI - 10.21542/gcsp.2020.22
Subject(s) - medicine , renal glucose reabsorption , diabetes mellitus , reabsorption , type 2 diabetes , transporter , paragraph , endocrinology , pharmacology , bioinformatics , kidney , chemistry , biology , biochemistry , world wide web , gene , computer science
[no abstract - showing first paragraph of article]Sodium-glucose co-transporter-2 (SGLT2) inhibitors are relatively new class of antihyperglycemic medication that is well established in the management of type 2 diabetes mellitus (DM). It has a unique mechanism of action that targets the kidneys through inhibiting 90% of glucose reabsorption.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom